LAS VEGAS, Feb. 12 /Xinhua-PRNewswire-FirstCall/ -- China Health Holding, Inc.(OTC Bulletin Board: CHHH), a development stage pharmaceutical company with the goal of becoming a leading developer, manufacturer, marketer and
distributor of pharmaceutical products and dietary supplements in China and
worldwide, announced today that it has promoted Mr. Yu, XiaoFei as the
President of the Company.
Julianna Lu, the Founder and CEO of China Health Holding, noted that the
Company has successfully attracted and retained a group of world class
scientific, pharmaceutical and Traditional Chinese Medicine, or TCM, experts
and experienced business advisors to serve on the Company's management team
and board of directors.
As vice president and director, Mr. Yu helped develop 134 natural herbal
products within China Health Holding's two core product lines: King of Herbs
and Taoist Medicines based on the accomplishment of five thousand years of
Traditional Chinese Medicine. In 2004, Mr. Yu was elected to the board of
directors and was appointed vice president. He was previously the president
and director of Beijing's Taoist Tantric & Toltec Research & Development
Centre and is currently a research consultant at the Central TSM Research &
Development Institute. He is also a professor at the University of CCCP, where
he teaches Taoism, Taoist Medicine and Indian classical philosophy and
religion. Prior to teaching at the University of CCCP, from 1994 to 1999, Mr.
Yu was an associate professor in Taoism, Taoist Medicine, Buddhism and
Scientific Philosophy at Beijing University.
"Since 2004, XiaoFei Yu has served China Health Holding in many
capacities," said Julianna Yu, Founder and CEO of China Health Holding. "Mr.
Yu has been instrumental in helping the Company acquire an extensive range of
China SFDA drugs as well as China GMP accredited manufacturing plants. His
ability to opportunistically select and consolidate acquired businesses has
been essential to the success of our business model in this highly fragmented
industry."
Mr. Yu's comprehensive experience in Traditional Chinese Medicine will
continue to help China Health Holding build its vertically integrated business
model. In the next 12 to 24 months, the Company's main objective remains to
continue partnering with China SFDA certified drugs producers, China GMP
accredited manufacturing facilities, research and development centers and
Universities. Further pending acquisitions are expected to bring total assets
to US$100 million, gross revenue of approximately US$100 million and an annual
net income of US$10-15 million.
About China Health Holding
China Health Holding, Inc. is a development stage company with the goal of
becoming a leading developer, manufacturer, marketer and distributor of
pharmaceutical products and dietary supplements in China and worldwide. It has
extensive expertise in the field of traditional Chinese medicine and the
Chinese pharmaceutical industry. Its immediate goal is the profitable
penetration of the growing global and China pharmaceutical industry and market
through acquisitions of major pharmaceutical companies in the People's
Republic of China and worldwide. Its long-term plans include the development
of a pharmaceutical drug pipeline and technology based on its knowledge of
traditional Chinese medicine and the pharmaceutical industry in the People's
Republic of China.
The company has two wholly-owned subsidiaries: (i) China Health World
Pharmaceutical Corporation, which will develop, manufacture and commercialize
natural medications for diseases and conditions related to diabetes,
cardiovascular disease and neurological disorders; and (ii) China Health World
Trade Corporation, which will develop China Health's retail/franchise
infrastructure along with worldwide branding, multimedia marketing and multi-
channel distribution to global customers and markets.
China Health owns the exclusive worldwide rights to a total of 134
proprietary natural herbal medicinal products/formulas in two natural herbal
medicinal product lines: King of Herbs and Taoist Medicinal. Please visit
http://www.chinahealthholding.com for the Company's profile.
For investor and media inquiries, please contact:
China Health Holding, Inc.
Mr. Yu, XiaoFei
President
Tel: 1-604-608-6788 and Tel: 1-877-883-0979
Tel: 86-10-1370-133-1287 (Beijing China)(Text Message)
Email: info@chinahealthholding.com
http://www.chinahealthholding.com
In the United States, and North America
Investor Relations International (Los Angeles)
Haris Tajyar, Managing Partner
Tel: 1-818-382-9702
In China, Hong Kong and Asia, Rest of World
Rory Macpherson
Consultant
Ogilvy Public Relations Worldwide
Office: 86-10-8520-6553
Safe Harbor Statement: To the extent that statements in the press release
are not strictly historical, including statements as to revenue projections,
business strategy, outlook, objectives, future milestones, plans, intentions,
goals, future financial conditions, future collaboration agreements, the
success of the Company's development, events conditioned on stockholder or
other approval, or otherwise as to future events, such statements are forward
looking, all forward-looking statements, whether written or oral, and whether
made by or on behalf of the Company, are expressly qualified by the cautionary
statements and any other cautionary statements, which may accompany the
forward-looking statements, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. The
forward-looking statements contained in this release are subject to certain
risks and uncertainties that could cause actual results to differ materially
from the statements made. Other important factors that could cause actual
results to differ materially include the following: business conditions and
the amount of growth in the Company's industry and general economy;
competitive factors; ability to attract and retain personnel; the price of the
Company's stock; and the risk factors set forth from time to time in the
Company's SEC reports, including but not limited to its annual report on Form
10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K. In
addition, the company disclaims any obligation to update or correct any
forward-looking statements in all of the Company's press releases to reflect
events or circumstances after the date hereof.